This site is intended for healthcare professionals outside the US.

DOUBLE THE TIME (PFS)

 

AFINITOR plus exemestane more than doubled median PFS for patients after recurrence or progression following an NSAI vs exemestane alone1

Early and sustained benefits with AFINITOR plus exemestane, based on local review1*†

"Early and sustained benefits with AFINITOR (everolimus) vs exemestane alone, based on local review. 90% of patients in both arms remained progression free at first assessment"
  • Patients treated with AFINITOR plus exemestane experienced a 55% reduction in the risk of progression or death vs exemestane alone1

Significant PFS benefit confirmed by independent review1,2*†

"Independent Review: Median progression-free survival (PFS) of 11 months with AFINITOR (everolimus) plus exemestane vs exemestane alone"
  • Patients treated with AFINITOR plus exemestane experienced a 62% reduction in the risk of progression or death vs exemestane alone1

AFINITOR plus exemestane demonstrated greater PFS benefit in the first-line metastatic setting vs exemestane alone in patients who experienced recurrence during or after (neo)adjuvant NSAI therapy, according to a post hoc exploratory analysis3

“Local Review: AFINITOR plus exemestane demonstrated greater PFS benefit in the first-line metastatic setting vs exemestane alone in patients who experienced recurrence during or after (neo)adjuvant NSAI therapy, according to a post hoc exploratory analysis”
  • Patients treated with AFINITOR plus exemestane in the first-line metastatic setting after (neo)adjuvant NSAI experienced a 61% reduction in the risk of progression or death vs exemestane alone3

PFS benefit in the first-line metastatic setting confirmed by independent review in patients who experienced recurrence during or after (neo)adjuvant NSAI therapy, according to a post hoc exploratory analysis3

“Independent Review: PFS benefit in the first-line metastatic setting confirmed by independent review in patients who experienced recurrence during or after (neo)adjuvant NSAI therapy, according to a post hoc exploratory analysis”
  • Patients treated with AFINITOR plus exemestane in the first-line metastatic setting after (neo)adjuvant NSAI experienced a 68% reduction in the risk of progression or death vs exemestane alone3

AFINITOR demonstrated a durable treatment benefit4

“AFINITOR (everolimus) plus exemestane more than doubled the number of patients progression free at 6, 12, and 18 months vs exemestane alone”
  • AFINITOR plus exemestane more than doubled the number of patients progression free at 6, 12, and 18 months4*
  • AFINITOR plus exemestane more than doubled median PFS, demonstrating a median PFS of 7.8 and 11.0 months vs 3.2 and 4.1 months by local and independent review, respectively1*
Abbreviations:
aBC, advanced breast cancer; BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; CI, confidence interval; HR, hazard ratio; HR+, hormone receptor-positive; NSAI, nonsteroidal aromatase inhibitor; PFS, progression-free survival.
*Versus exemestane alone.
With kind permission from Springer Science+Business Media: Adv Ther Everolimus PLus Exemestane in Postmenopausal Patients With HR(+) Breast Cancer BOLERO-2 Final Progression-Free Survival Analysis. 2013;30(10):870-884. Yardley DA. Noguchi S, Pritchard KI, et al. Figure 1.
References:
1. AFINITOR [summary of product characteristics]. Novartis Pharma AG; 2017.
2. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOELRO-2 final progression-free survival analysis Adv Ther. 2013;30(10):870-884.
3. Beck JT. Hortobagyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR+, HER2-advanced breast cancer in BOLERO-2. Breast Cancer Res Treat. 2014:143(3):459-467.
4. Data on file. Novartis Pharma AG.